EXEL
Exelixis, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$69.39Close
$18.2BMarket cap
$37.90 – $69.3952-week range
Late-januaryNext report · estimated
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 93 · stronger than 93% of stocks over 12 months
- RS line at a 1-year high outperforming the S&P 500 more than at any point this year
- Near its high at its 52-week high
- Accumulation up-day volume 1.5× down-day volume over 50 sessions
- Earnings growing EPS +23% year on year
Cautions
- Extended 6.2 ATR above its 50-day average
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
0%
1wk
up 7.5%
price change
1mo
up 18.8%
price change
12-month return
up 78%
market up 11% ·
its own up 65%
F-score
7 / 9
Strong
Altman Z
18.23
Low risk
P/E
23.3×
price / earnings
PEG
0.40
P/E / EPS growth
P/B
8.4×
price / book
Earnings yield
up 4.9%
EBIT / enterprise value
Cheaper than
50%
of the market · around average
Revenue growth
up 7%
year on year
EPS growth
up 23%
latest quarter · -3 pts
Sales growth
up 10%
latest quarter · -0 pts
ROE
up 36%
return on equity
Free cash margin
up 38%
$875.8M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-0.5×
net cash
Interest cover
—EBIT / interest
Piotroski tests
- short-term liquidity weakened
- gross margin narrowed
- profitable on its assets
- generating cash from operations
- profitability improving
- profits backed by cash
- reduced long-term debt
- no new shares issued
- assets working harder
Trade setup
ATR%
2.7%
$1.89 a day · 2×ATR $65.61
RS
93 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
2.3×
vs 50-day average
Up/down volume
1.53
50 sessions
Implied move
—
no scheduled report
Trend template · 8 of 8
Screen verdict
-
Stage 2 Leader in mixed conditions
- RS 93
- Trend 8/8
- Off 12-month high 0%
- EPS growth +23% (accel -3 pts)
- Sales growth +10% (accel -0 pts)
- Altman Z 18.23 (low risk)
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Oct 29, 2026
Results reaction
Oct 29, 2026+7% vs market2 sessions after results
Financials
- Gross 96%
- Net 34%
- Free cash 38%
- Cash
- Long-term debt
| FY2020Jan 1, 2021 | FY2021Dec 31, 2021 | FY2022Dec 30, 2022 | FY2023Dec 29, 2023 | FY2024Jan 3, 2025 | FY2025Jan 2, 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $987.5M | $1.4B | $1.6B | $1.8B | $2.2B | $2.3B |
| Gross margin | 96% | 96% | 96% | 96% | 96% | 96% |
| Operating income | $110.1M | $286.7M | $201.5M | $170.9M | $604.6M | $872.2M |
| Net income | $111.8M | $231.1M | $182.3M | $207.8M | $521.3M | $782.6M |
| Net margin | 11% | 16% | 11% | 11% | 24% | 34% |
| Earnings per share | $0.35 | $0.72 | $0.56 | $0.65 | $1.76 | $2.78 |
| Free cash flow | $178.6M | $346.6M | $334.9M | $292.9M | $671.5M | $875.8M |
| Free cash margin | 18% | 24% | 21% | 16% | 31% | 38% |
| Cash | $319.2M | $647.2M | $501.2M | $263.0M | $217.4M | $482.5M |
| Shareholders' equity | $1.9B | $2.2B | $2.5B | $2.3B | $2.2B | $2.2B |
| Shares outstanding | 311.63m | 318.84m | 323.95m | 302.79m | 281.73m | 262.48m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 29, 2026 | Quarterly ↗ | Oct 2, 2026 | 27d |
| Aug 5, 2026 | Quarterly ↗ | Jul 3, 2026 | 33d |
| May 5, 2026 | Quarterly ↗ | Apr 3, 2026 | 32d |
| Feb 10, 2026 | Annual ↗ | Jan 2, 2026 | 39d |
| Nov 4, 2025 | Quarterly ↗ | Oct 3, 2025 | 32d |
| Jul 28, 2025 | Quarterly ↗ | Jul 4, 2025 | 24d |
| May 13, 2025 | Quarterly ↗ | Apr 4, 2025 | 39d |
| Feb 11, 2025 | Annual ↗ | Jan 3, 2025 | 39d |
| Oct 29, 2024 | Quarterly ↗ | Sep 27, 2024 | 32d |
| Aug 6, 2024 | Quarterly ↗ | Jun 28, 2024 | 39d |
| Apr 30, 2024 | Quarterly ↗ | Mar 29, 2024 | 32d |
| Feb 6, 2024 | Annual ↗ | Dec 29, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Results ↗ |
| Sep 11, 2026 | Other events ↗ |
| Aug 31, 2026 | Other events ↗ |
| Aug 5, 2026 | Results ↗ |
| May 29, 2026 | Director or officer change · Shareholder vote ↗ |
| May 5, 2026 | Results · Other events ↗ |
| Feb 10, 2026 | Results ↗ |
| Jan 12, 2026 | Results ↗ |
| Nov 7, 2025 | Director or officer change · Other events ↗ |
| Nov 4, 2025 | Results · Other events ↗ |
| Aug 29, 2025 | Director or officer change ↗ |
| Jul 28, 2025 | Results ↗ |